Redx Pharma plc Redx to Participate at Piper Sandler Conference (9275T)
30 Noviembre 2021 - 1:00AM
UK Regulatory
TIDMREDX
RNS Number : 9275T
Redx Pharma plc
30 November 2021
REDX PHARMA PLC
("Redx" or the "Company")
Redx to Participate at the Piper Sandler 33rd Annual Virtual
Healthcare Conference
Alderley Park, UK, 30 November 2021 - Redx Pharma (AIM: REDX),
the clinical-stage biotechnology company focused on discovering and
developing novel, small molecule, highly targeted therapeutics for
the treatment of cancer and fibrotic disease, announces that Lisa
Anson, Chief Executive Officer, and Peter Collum, Chief Financial
Officer, will be participating at the Piper Sandler 33rd Annual
Virtual Healthcare Conference, 30 November to 2 December.
A pre-recorded presentation by Lisa Anson can be accessed via
the following link: https://bit.ly/3CSvvSV
For further information, please contact:
Redx Pharma Plc T: +44 (0)1625 469
918
UK Headquarters
Lisa Anson, Chief Executive Officer
Karl Hård, Head of Investor Relations
k.hard@redxpharma.com
US Office
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368
3550
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker) T: +44 (0)203 705
9330
Claes Spång/ Satheesh Nadarajah/ David
Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886
2500
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting T: +44 (0)203 727
1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology
company focused on the discovery and development of novel, small
molecule, highly targeted therapeutics for the treatment of cancer
and fibrotic disease, aiming initially to progress them to clinical
proof of concept before evaluating options for further development
and potential value creation. Redx's lead oncology product
candidate, the Porcupine inhibitor RXC004, commenced a Phase 2
programme in November 2021. The Company's selective ROCK2 inhibitor
product candidate, RXC007, is in development for idiopathic
pulmonary fibrosis and commenced a Phase 1 clinical trial in June
2021. Initial results were reported in October 2021, with full
Phase 1 results expected in 2022.
The Company has a strong track record of discovering new drug
candidates through its core strengths in medicinal chemistry and
translational science, enabling the Company to discover and develop
differentiated therapeutics against biologically or clinically
validated targets. The Company's accomplishments are evidenced not
only by the two wholly-owned clinical-stage product candidates and
rapidly expanding pipeline, but also by the four strategic
transactions from which has emerged the most advanced product
candidate pirtobrutinib (RXC005, LOXO-305), a BTK inhibitor now in
Phase 3 clinical development by Eli Lilly following its acquisition
of Loxo Oncology. In addition, Redx has forged pre-clinical
collaborations with AstraZeneca and Jazz Pharmaceuticals.
To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKCBBPBDDDDB
(END) Dow Jones Newswires
November 30, 2021 02:00 ET (07:00 GMT)
Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De May 2023 a May 2024